The main functions and effects of baricitinib/alemin

Baricitinib is a selective oral JAK inhibitor jointly developed by Eli Lilly and Incyte. This drug precisely blocks the Janus kinase (JAK1 and JAK2) signaling pathway and inhibits the transmission of multiple inflammatory factors, thereby regulating the excessive response of the immune system. Initially approved for the treatment of moderate to severe rheumatoid arthritis, it was subsequently expanded internationally for the adjuvant treatment of alopecia areata and COVID-19-related inflammatory reactions. Its extensive anti-inflammatory mechanism makes it one of the most popular immunomodulatory drugs in recent years.

In the treatment of rheumatoid arthritis, the main effects of baricitinib are to reduce joint inflammation, improve pain and morning stiffness, and delay joint structural damage. Compared with traditional biologics, its oral form brings higher compliance and also shows certain clinical advantages for refractory patients. By blocking the signaling pathways mediated by cytokines (such asIL-6, IFN-γ, etc.), it effectively inhibits the immune inflammatory response, reduces abnormal synovial cell proliferation, and fundamentally improves the course of arthritis.

In recent years, the scope of application of baricitinib has continued to expand. In 2022, the US FDA officially approved it for the treatment of patients with severe alopecia areata (Alopecia Areata), becoming the first systemic oral treatment drug. It regulates the inflammatory pathway of immune attack on hair follicles, restores hair follicles to their normal growth cycle, promotes hair regeneration, and brings breakthrough progress to people who have long been troubled by alopecia areata. At the same time, baricitinib has shown significant itching relief and skin repair effects in patients with atopic dermatitis, and is regarded as a new option for oral small molecule treatment.

In addition, in the treatment of severe patients with new coronavirus pneumonia (COVID-19), baricitinib has been proven to reduce inflammatory storms and improve oxygenation indicators. Some countries have included it in emergency use or recommended in guidelines. Its mechanism is different from that of glucocorticoids, which can help regulate cytokine levels and reduce the length of hospitalization and the risk of death.

Reference materials:https://go.drugbank.com/drugs/DB11817